MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$2,237K
Free Cash flow
-$2,461K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from share issuance
    • Stock-based compensation expense
    • Trade and other payables
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Share repurchase
    • Share issuance costs
    • Others
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Effect of exchange rate changes on cash
-
-388
269
-
Net loss
-3,883
-6,521
-6,407
-46,885
Depreciation and amortization
65
59
66
246
Unrealized loss on foreign currency remeasurement
25
-24
-13
-294
Stock-based compensation expense
1,469
2,279
2,626
2,609
Change in fair value of warrant liabilities
-380
-
-
21,925
Prepaid expenses and other current assets
-26
-51
-299
189
R&d tax incentive
186
558
364
-5,579
Trade and other payables
458
44
-5,396
1,385
Non-cash expense of eloc commitment
0
-
-
1,048
Change in fair value of convertible rights
0
-
-
-299
Non-cash interest expense
0
-
-
302
Loss on extinguishment
0
-
-
-1,472
Securities pledged
0
-
-
-
Net cash used in operating activities
-2,456
-4,622
-9,163
-12,513
Purchase of property, plant and equipment
5
4
2
8
Investment of joint venture
13
0
40
-
Net cash used in investing activities
-18
-4
-42
-8
Proceeds from share issuance
6,955
2,197
69,465
48,343
Share issuance costs
823
91
2,288
747
Warrant issuance costs
284
-
-
125
Share repurchase
1,138
1,179
-
-
Proceeds received from facility agreement
0
-
-
4,282
Repayment of facility agreement
0
-
-
4,459
Proceeds from issuance of convertible debt
0
-
-
2,779
Cancellation of warrants
-
-
-
24,769
Repayment of convertible debt
0
-
-
3,795
Debt issuance costs
0
-
-
113
Net cash provided by financing activities
4,710
927
67,177
21,396
Net increase in cash and cash equivalents
2,237
-3,700
57,972
8,875
Cash and cash equivalents at beginning of period
73,280
73,280
15,039
-
Cash and cash equivalents at end of period
74,450
69,193
73,280
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from shareissuance$6,955K Net cash provided byfinancing activities$4,710K Canceled cashflow$2,245K Net increase in cashand cash...$2,237K Canceled cashflow$2,474K Share repurchase$1,138K Share issuance costs$823K Warrant issuance costs$284K Stock-based compensationexpense$1,469K Trade and otherpayables$458K Depreciation andamortization$65K Prepaid expenses andother current assets-$26K Net cash used inoperating activities-$2,456K Net cash used ininvesting activities-$18K Canceled cashflow$2,018K Net loss-$3,883K Investment of joint venture$13K Purchase of property,plant and equipment$5K Change in fair value ofwarrant liabilities-$380K R&d tax incentive$186K Unrealized loss on foreigncurrency remeasurement$25K

Incannex Healthcare Inc. (IXHL)

Incannex Healthcare Inc. (IXHL)